Product Categories
Contact Us
Contact Person: Garry
Skype: spy3344
Whats app: +86 18702759822
MK-1439 NNRT New HIV Med Doravirine

MK-1439 NNRT New HIV Med Doravirine

Product introduction Best MK-1439 Peptides Whatsapp:+8618123940985 Skype:shucanlynn CAS 1338225-97-0 Sample:Available Price: Negotiable Customized blend :Available Standard: SGS,ISO9001,KOSHER Name:MK-1439 Other name:Doravirine MF:C17H11ClF3N5O3 MW:425.7491496...

  • Features & Specification

    Product introduction

    Best MK-1439 Peptides

    Whatsapp:+86 18123940985


    CAS 1338225-97-0


    Price: Negotiable

    Customized blend :Available

    Standard: SGS,ISO9001,KOSHER 



    Other name:Doravirine


    MK-1439 Dosage

    Adult Dose: One tablet once a day. Each tablet contains 100mg doravirine + 300mg tenofovir disoproxil fumarate + 300mg lamivudine. 

    MK-1439 is an experimental HIV medication. It contains three different types of HIV drugs: one non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). It is currently in Phase III clinical trials. 

    MK-1439 is a single-tablet regimen containing generic versions of two currently approved HIV medications (tenofovir disoproxil fumarate and lamivudine) and one experimental HIV medication (doravirine). 

    MK-1439 Description 

    Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor under development . for use in the treatment of HIV/AIDS. Doravirine demonstrated robust antiviral activity and good tolerability in a small clinical study of 7-day monotherapy reported at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013. Doravirine appeared safe and generally well-tolerated with most adverse events being mild-to-moderate. 


    Brief Summary: 

    To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Extension Study. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA or EPZICOM/KIVEXA, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.


    SARMs List

    MK-2866 (Ostarine)
    RAD-140 (Testolone)
    MK-677 (Ibutamoren; Nutrobal)
    LGD-4033 (Ligandrol; Anabolicum)
    S4 (Andarine)
    SR9009 (Stenabolic)


    Please feel free contact me

    Whatsapp:+86 18123940985


Hot Tags: MK-1439 nnrt new HIV med doravirine, China, suppliers, factory, buy, price, quotation, free sample
Related Products